About Alpha/beta hydrolase domain-containing protein 17B
Alpha/beta hydrolase domain-containing protein 17B (ABHD17B) is a protein
from Homo sapiens identified by UniProt accession
Q5VST6, 288 residues long.
MolForge cross-references it against 0 known binders and
116 disease associations.
Target properties
| Protein name | Alpha/beta hydrolase domain-containing protein 17B |
| UniProt accession | Q5VST6 |
| Gene | ABHD17B |
| Organism | Homo sapiens |
| Length | 288 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (116)
Diseases linked to this target (Open Targets).
- adolescent idiopathic scoliosis · score 0.08
- Familial ocular anterior segment mesenchymal dysgenesis · score 0.07
- Fuchs endothelial corneal dystrophy · score 0.07
- Familial exudative vitreoretinopathy · score 0.06
- major depressive disorder · score 0.06
- retinitis pigmentosa · score 0.06
- macular corneal dystrophy · score 0.06
- X-linked endothelial corneal dystrophy · score 0.06
- age-related macular degeneration · score 0.06
- cataract 50 with or without glaucoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5VST6-F1 | alphafold | PREDICTED | 92.20 | — |
Amino-acid sequence (288 residues)
MNNLSFSELC CLFCCPPCPG KIASKLAFLP PDPTYTLMCD ESGSRWTLHL SERADWQYSS REKDAIECFM TRTSKGNRIA CMFVRCSPNA KYTLLFSHGN AVDLGQMSSF YIGLGSRINC NIFSYDYSGY GASSGKPTEK NLYADIEAAW LALRTRYGIR PENVIIYGQS IGTVPSVDLA ARYESAAVIL HSPLTSGMRV AFPDTKKTYC FDAFPNIDKI SKITSPVLII HGTEDEVIDF SHGLALFERC QRPVEPLWVE GAGHNDVELY GQYLERLKQF VSQELVNL
Explore Alpha/beta hydrolase domain-containing protein 17B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets